Award Number: DAMD17-98-1-8484

TITLE: Phase I NKX3.1 in Prostate

PRINCIPAL INVESTIGATOR: Edward P. Gelmann, M.D.

CONTRACTING ORGANIZATION: Georgetown University
Washington, DC 20007-2197

REPORT DATE: January 2001

TYPE OF REPORT: Final, Phase I

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
We have isolated a prostate-specific gene, *NKX3.1*, that maps to chromosome 8p21, a common region for loss of heterozygosity in human prostate cancer. *NKX3.1* is a homeobox gene that is expressed at high levels in adult human prostate. Deletion of *NKX3.1* in the mouse has suggested that *NKX3.1* has a suppressor effect on prostatic epithelial cell growth, and that haploinsufficiency is sufficient to produce epithelial hyperplasia. Inconsistent with the interpretation that *NKX3.1* is a classical tumor suppressor gene, the coding region of *NKX3.1* is not mutated in human prostate cancer. We have generated an antibody highly specific for *NKX3.1*. Using this reagent we have shown that loss of *NKX3.1* expression is increasingly likely with prostate tumor progression. This loss of expression ranges from 16% of radical prostatectomy specimens to 80% in metastases. We have shown that a genetic polymorphism (*NKX3.1* R52C) that changes DNA-binding properties of the *NKX3.1* protein is present in approximately 10% of the human population. We have not found a difference in the frequency of *NKX3.1* R52C between Caucasians and African Americans. The polymorphism is a risk factor for aggressive prostate cancer (high grade or high stage) (RR=1.8, 95%CI = 1.01-3.22).
# Table of Contents

- Cover
- SF 298
- Introduction ........................................... 3
- Body ..................................................... 3
- Key Research Accomplishments ......................... 6
- Reportable Outcomes ..................................... 6
- Conclusions ............................................. 7
- References ............................................. 7
- Appendices ............................................. 7
Introduction

We have isolated a prostate-specific gene, NKX3.1, that maps to chromosome 8p21, a common region for loss of heterozygosity in human prostate cancer. NKX3.1 is a homeobox gene. The mRNA is expressed at high levels in adult human prostate, at very low levels in testis and in no other tissues (1,2). Expression of NKX3.1 is androgen-regulated (1). Moreover, mice either heterozygous or homozygous for deletion of NKX3.1 had prostatic hyperplasia and an elevated growth fraction of prostatic epithelial cells (2). This implied that NKX3.1 has a suppressor effect on prostatic epithelial cell growth, and that haploinsufficiency was sufficient to produce epithelial hyperplasia. Inconsistent with the interpretation that NKX3.1 is a classical tumor suppressor gene, the coding region of NKX3.1 is not mutated in human prostate cancer (3). However, disruption of a single allele or diminished expression of NKX3.1 may occur in human prostate cancer and contribute to prostate neoplasia. We previously had reported that the human population had a polymorphism in NKX3.1 that changed amino acid 52 from arginine to cysteine (R52C) to generate a variant protein (3). The polymorphism disrupts a consensus phosphorylation sequence and abrogates dependence of DNA binding on phosphorylation in vitro. This provided a basis for asking about the role of R52C in prostate cancer risk.

Body

The approved Statement of Work had five aims. This Statement of Work anticipated a budget of $125,000. The project was funded at 75% of the requested support level. This progress report is organized under headings of each of the aims of the original Statement of Work.

Aim 1: Mutational analysis of the NKX3.1 promoter region

The original human genomic clone of NKX3.1 contained 1.3 kb of 5’ untranslated region. We found this region to have little or no transcriptional activity when placed upstream from a luciferase reporter construct. We spent much of the last year cloning a putative 5’ UTR from a phage λ human genomic DNA library. However, nucleotide sequencing of nearly 16 kb revealed that there was no overlap with the 1.3 kb of known 5’ untranslated NKX3.1 sequence. Since this information is relatively recent, we have no further progress to report on this part of Aim 1.

In addition to promoter mutation, a second potential mechanism for regulation of NKX3.1 expression in human tissues and tumors is promoter methylation. To begin to assess the role that gene methylation may play in NKX3.1 expression, we studied the effect of 5-azacytidine (5-AC), a demethylase inhibitor, on the expression of NKX3.1 in prostate cancer cells. 5-AC has a complex effect on the expression of NKX3.1 in LNCaP cells (Figure 1). At 24 hours 1μM markedly increased expression. At 48 hours of treatment both 1 and 5 μM increased expression. However after 72 hours of treatment expression of NKX3.1 in LNCaP cells returned to baseline. We are continuing to study the regulation of NKX3.1 by methylation and are examining the effect of 5-AC in prostate cancer cell lines that do not express NKX3.1.

Aim 2: NKX3.1 R52C polymorphism in racial groups and in prostate cancer patients and controls

Using the Taqman assay described in our proposal we determined NKX3.1 genotype in a cohort of 558 men with prostate cancer from the Physicians Health Study and 695 age-matched controls. The results for the total study population shown in Table 1 show no statistically significant difference between the two groups.
When we analyzed only men who presented with aggressive prostate cancer defined as stage C or D or Gleason score ≥ 7, we found a statistically significant increase in the frequency of NKX3.1 R52C among the cases, RR=1.8 (CI = 1.01-3.22). No differences between cases and controls were found for nonaggressive cancers or those men with unknown stage and grade.

Table 1

<table>
<thead>
<tr>
<th>NKX3.1 genotype</th>
<th>No. Cases (%)</th>
<th>No. Controls (%)</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>499 (89.4)</td>
<td>637 (91.7)</td>
<td>1.00</td>
<td>Reference</td>
</tr>
<tr>
<td>CT</td>
<td>57 (10.2)</td>
<td>55 (7.9)</td>
<td>1.32</td>
<td>0.90-1.95</td>
</tr>
<tr>
<td>TT</td>
<td>2 (0.4)</td>
<td>3 (0.4)</td>
<td>0.85</td>
<td>0.14-5.11</td>
</tr>
<tr>
<td>CT+TT</td>
<td></td>
<td></td>
<td>1.30</td>
<td>0.89-1.90</td>
</tr>
<tr>
<td>Nonaggressive Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>234 (90.4)</td>
<td>285 (89.6)</td>
<td>1.00</td>
<td>Reference</td>
</tr>
<tr>
<td>CT</td>
<td>25 (9.7)</td>
<td>31 (9.8)</td>
<td>0.98</td>
<td>0.56-1.71</td>
</tr>
<tr>
<td>TT</td>
<td>0</td>
<td>2 (0.6)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CT+TT</td>
<td></td>
<td></td>
<td>0.92</td>
<td>0.53-1.60</td>
</tr>
<tr>
<td>Aggressive Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>229 (88.8)</td>
<td>313 (93.4)</td>
<td>1.00</td>
<td>Reference</td>
</tr>
<tr>
<td>CT</td>
<td>27 (10.5)</td>
<td>21 (6.3)</td>
<td>1.76</td>
<td>0.97-3.19</td>
</tr>
<tr>
<td>TT</td>
<td>2 (0.8)</td>
<td>1 (0.3)</td>
<td>2.73</td>
<td>0.25-30.33</td>
</tr>
<tr>
<td>CT+TT</td>
<td></td>
<td></td>
<td>1.80</td>
<td>1.01-3.22</td>
</tr>
<tr>
<td>Unknown Aggressiveness</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>36 (87.8)</td>
<td>39 (92.9)</td>
<td>1.00</td>
<td>Reference</td>
</tr>
<tr>
<td>CT</td>
<td>5 (12.2)</td>
<td>3 (7.1)</td>
<td>1.81</td>
<td>0.40-8.10</td>
</tr>
<tr>
<td>TT</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CT+TT</td>
<td></td>
<td></td>
<td>1.81</td>
<td>0.40-8.10</td>
</tr>
</tbody>
</table>

Aggressive cancer were those cases identified at presentation as stages C or D or Gleason score ≥7.
Since the Physicians Health Study cohort was composed mostly of Caucasians, we have used a smaller cohort from Richard Hayes, PhD, of the National Cancer Institute, to determine the racial distribution of the \textit{NKX3.1} R52C polymorphism (4). The data shown in Table 2 demonstrate that there are no differences in the frequency of the NKX3.1 R52C variant protein between African Americans and Caucasians.

**Table 2**

**NKX3.1 Genotype in White and Black American Men**

<table>
<thead>
<tr>
<th>RACE</th>
<th>C/C</th>
<th>C/T</th>
<th>T/T</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>116 (87.9%)</td>
<td>15</td>
<td>1</td>
<td>132</td>
</tr>
<tr>
<td>Black</td>
<td>103 (90.35%)</td>
<td>9</td>
<td>2</td>
<td>114</td>
</tr>
<tr>
<td>Total</td>
<td>219 (89.0%)</td>
<td>24</td>
<td>3</td>
<td>246</td>
</tr>
</tbody>
</table>

**Aim 3: Immunohistochemical detection of NKX3.1 protein in prostate cancer tissues.**

We generated a rabbit antiserum to recombinant human NKX3.1 protein. The antiserum was used to study expression of NKX3.1 in normal human tissues and prostate cancer. This work has been published and is included as an appendix to this report (5). Among normal human tissues NKX3.1 expression was seen in testis, in rare pulmonary mucous glands, and in isolated regions of transitional epithelium of the ureter. NKX3.1 was uniformly expressed in nuclei of normal prostate epithelial cells in 61 histologic sections from radical prostatectomy specimens. We analyzed 507 samples of neoplastic prostate epithelium, most of which were contained on a tissue microarray that contained samples from different stages of prostatic neoplasia. We observed complete loss of NKX3.1 expression in 5\% of benign prostatic hyperplasia, 20\% of high-grade prostatic intraepithelial neoplasia, 6\% of T1a/b samples, 22\% of T3/4 samples, 34\% of hormone-refractory prostate cancer, and 78\% of metastases. Our data show that NKX3.1 expression is highly, but not exclusively, specific for the prostate. Loss of NKX3.1 expression is strongly associated with hormone-refractory disease and advanced tumor stage in prostate cancer ($p < 0.0001$).

**Aim 4: Identify the effect of NKX3.1 expression on prostate cancer phenotype in cultured cells**

We have transfected \textit{NKX3.1} expression vectors into TSU-Pr1 human prostate cancer cells. We saw no effect of NKX3.1 expression on in vitro cell growth or morphology of TSU-Pr1 cells. A growth curve is shown in Figure 2. Interestingly, the cells are not indifferent to the expression of NKX3.1 since in the absence of continuous antibiotic selective pressure, the NKX3.1 expression plasmid is lost. In the future as part of phase II of this project we will examine the effect of NKX3.1 on the growth of TSU-Pr1 cells in nude mice. Preliminary data from our phase II project suggest that \textit{NKX3.1} affects in vivo growth probably by increasing apoptotic rate of cells expressing the gene (Figure 3). The data in Figure 3 were not generated as part of phase I. The animal experiments were not
performed with DOD funding. We have also found that in vitro NKX3.1 expression sensitizes cells to induction of cell death by physical and chemical agents. In both stably transfected and transiently transfected TSU-Prl cells we have found that NKX3.1 expression nearly doubles the cell death response to irradiation or okadaic acid treatment. Representative data from transient transfection experiments are shown in Figure 4. Full length NKX3.1 protein expression caused a 1.7-fold increased cell death three days after exposure to 20 Gy irradiation. Constructs that were truncated at amino acid 184 eliminated a C-terminal region that attenuated NKX3.1 transcriptional activation (6). The R52C mutation had a negative effect on activation of protein activity by deletion of the C-terminal sequence. A negative control was the gene inserted in reverse orientation in the expression vector.

Aim 5: Determine if RT-PCR for NKX3.1 can be applied to detect circulating prostate cancer cells

Expression of NKX3.1 is highly restricted in the mouse to prostatic lobes and bulbourethral gland (2). NKX3.1 expression is less tightly controlled in adult human tissues. There is a low level of expression in the testis and a faint signal on northern blots of peripheral blood mononuclear cell RNA. We tested whether NKX3.1 could be used in human blood samples to detect low levels of prostatic carcinoma cells. However, we found that with nested PCR reactions we could detect NKX3.1 sequences in the blood of normal men and women. We therefore have concluded that NKX3.1 will not be a useful marker for detection of circulating micrometastatic prostatic cells in patients with prostate cancer.

Key Research Accomplishments

- Determined frequency of NKX3.1 R52C polymorphism in the population and in cancer patients
- Showed that there NKX3.1 R52C variant is present with equal frequency in blacks and whites
- Demonstrated that NKX3.1 R52C is a risk factor for aggressive prostate cancer
- Developed a rabbit antiserum to human NKX3.1
- Demonstrated loss of NKX3.1 expression in prostate cancer increases with tumor progression
- Identified normal tissues that express NKX3.1

Reportable Outcomes

1. Funding applied for and received:

Genetic polymorphisms in prostate cancer
NIEHS ES-09888
PI - Edward Gelmann
2. Employment or research opportunities

David Steadman, PhD
Postdoctoral fellow received funding in 1999 from the US Army prostate cancer research program for studies of the biochemistry of NKX3.1 binding to DNA.

Conclusions

This is the final report of phase I of our project NKX3.1 in Prostate Cancer. We have successfully accomplished four of the five original aims despite receiving only 75% of requested funding. We have demonstrated that NKX3.1 expression decreases during prostate cancer progression. This implies that loss of NKX3.1 expression may favor tumor progression and more aggressive cancer. A variant NKX3.1 protein NKX3.1 R52C, present in approximately 10% of the population, is a risk factor for aggressive prostate cancer. We have demonstrated a model system for the study of NKX3.1 effect on cell death in vitro. Future studies will examine the interaction between NKX3.1 and the cell death mechanism, will determine if loss of NKX3.1 expression in primary prostate cancer has prognostic significance and will readdress the control of NKX3.1 expression by promoter methylation.

References


Appendix

Loss of NKX3.1 Expression in Human Prostate Cancers Correlates with Tumor Progression


Lombardi Cancer Center (C. B., H. J. V., R. S., G. S., E. P. G.) and Department of Pathology (E. E. L.), Georgetown University, Washington, DC 20007-2007; Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892-4670 (L. B., J. K., O.-P. K.); Institute for Pathology (L. B., N. W. G.) and Urologic Clinics (T. C. G.), University of Basel, Basel, Switzerland; Laboratory of Cancer Genetics, Tampere University Hospital, Tampere, Finland (P. K.)

ABSTRACT

NKX3.1 is a prostate-specific homeobox gene located on chromosome 8p21. In the mouse, Nkx3.1 has growth-suppressive and differentiating effects on prostatic epithelium. Mutations of the coding region of NKX3.1 were not found in human prostate cancer, failing to support the notion that NKX3.1 was a tumor suppressor gene. To study the expression of NKX3.1 protein in human tissues and prostate cancer, we derived a rabbit antiserum against purified recombinant NKX3.1. Among normal human tissues, NKX3.1 expression was seen in testis, in rare pulmonary mucous glands, and in isolated regions of transitional epithelium of the ureter. NKX3.1 was uniformly expressed in nuclei of normal prostate epithelial cells in 61 histological sections from radical prostatectomy specimens. We analyzed 507 samples of neoplastic prostate epithelium, most of which were contained on a tissue microarray that contained samples from different stages of prostatic neoplasia. We observed complete loss of NKX3.1 expression in 5% of benign prostatic hyperplasia, 20% of high-grade prostatic intraepithelial neoplasia, 6% of T1ab samples, 22% of T3/4 samples, 34% of hormone-refractory prostate cancers, and 78% of metastases. Our data show that NKX3.1 expression is highly, but not exclusively, specific for the prostate. Loss of NKX3.1 expression is strongly associated with hormone-refractory disease and advanced tumor stage in prostate cancer (P < 0.0001).

INTRODUCTION

NKX3.1 is a homeobox gene with prostate-specific expression in the adult (1). NKX3.1 maps to chromosome 8p21, a region that undergoes LOH in ~75% of prostate cancer specimens (2–6). For this reason, NKX3.1 was a candidate target gene for disruption by the loss of heterozygosity (LOH) in prostate cancer tissues (2). Disruption of prostate epithelial morphology and dysplasia is more severe in Nkx3.1-null mice (7). The discovery of a mouse model in which theApplicant. to study its expression in human prostate cancer specimens. This report describes the derivation of an antiserum against purified recombinant NKX3.1 protein and the immunohistochemical expression of NKX3.1 in normal human tissues and in prostate cancer specimens. One report of NKX3.1 mRNA expression in human prostate cancer tissues described increased expression in prostate cancers compared with adjacent normal tissue (8). Our data examining NKX3.1 protein expression support the opposite conclusion. We demonstrate that loss of the expression of this growth suppressor correlates with prostate tumor progression.

MATERIALS AND METHODS

Expression and Purification of NKX3.1 Recombinant Protein. A 3'-truncated cDNA of wild-type NKX3.1, including nucleotides 1–581 and excluding the region that codes for the COOH-terminal region of the protein downstream from the homeodomain, was inserted into pMAL-C2g vector (New England Biolabs, Waltham, MA) at the SalI and EcoRI restriction sites. Fusion plasmid was transformed into BL-21-competent cells (Strategene, La Jolla, CA). An overnight culture of bacteria containing the fusion plasmid was induced with 0.5 mM IPTG for 2 h. MBP-NKX fusion protein was purified by affinity chromatography with amylose resin (New England Biolabs). Purified fusion protein was cleaved with 0.05 µg of genenase I (New England Biolabs) per 10 µg of fusion protein at room temperature for 24 h. Recombinant NKX3.1 protein generated with DEAE ion exchange chromatography.

Production of NKX3.1 Polyclonal Antibody. Twenty-five µg of purified NKX3.1 recombinant protein in TiterMax adjuvant emulsion (CytRx Corporation, Norcross, GA) were inoculated into New Zealand White rabbits. The total volume of the initial inoculation was 400 µl, and a 200-µl boost was administered 3–4 weeks later. Rabbits were tested 3–4 weeks after the initial inoculation and after the second boost. Rabbit anti-NKX3.1 antibody was purified by affinity chromatography by successive passes through BL-21-MBP CNBr-activated Sepharose 4B (Amersham Pharmacia Biotech, Uppsala, Sweden) followed NKX3.1 CNBr-activated Sepharose 4B.

Immunohistochemical Staining. Deparaffinized tissue sections were preheated in 10 mM sodium citrate solution for 20 min in a Black and Decker vegetable steamer. NKX3.1 antibody diluted 1:1000 in blocking buffer (1:70 dilution of goat serum in PBS) was incubated on slides for 1 h at room temperature. Sections were then incubated with 1:200 diluted biotinylated secondary antibody (Vector Labs, Burlingame, CA) for 30 min and ABC solution (Vector Labs) for 30 min. VIP peroxidase substrate (Vector Labs) was used to stain tissues, which were then counterstained with methyl green.
These questions were tested using a Jonkheere-Terpstra test as implemented in StatXact (Cytel). Unless specified below, all tests were considered significant if \( P < 0.05 \). To control for the two tests using HR or metastatic tumors as the sixth tissue type, the decrease in NKX3.1 expression was considered significant if the two-sided \( P \) was <0.025. Specific pairwise comparisons with BPH through T3/4 were performed for HR or metastatic tumors provided the overall test was significant. Similarly, the two comparisons of T1ab with either T3/4 or metastatic tissue were considered significant for \( P < 0.025 \).

**RESULTS**

Recombinant NKX3.1 was made as an MBP fusion protein in *Escherichia coli*. Cleavage of the fusion protein with genenase yielded electrophoretically pure NKX3.1 (Fig. 1A). Antibody to MBP did not react with cleaved NKX3.1, indicating complete cleavage of NKX3.1 from the fusion protein (Fig. 1B). Rabbit antiserum derived against purified recombinant NKX3.1 reacted only with NKX3.1 on Western blot and not with either E. coli proteins or MBP (Fig. 1C). The antiserum recognized 32-kDa NKX3.1 in TSU-Prl cells transfected with an NKX3.1 expression plasmid, but detected no proteins in TSU-Prl cells because they express \(<1/100\) the level of NKX3.1 mRNA found in LNCaP cells (Fig. 1D).\(^5\) The induction of NKX3.1 mRNA by androgen treatment of LNCaP cells has been described and was reflected in the induction of NKX3.1 protein after R1881 treatment of LNCaP cells (Fig. 1D; Refs. 1, 12).

The expression of NKX3.1 mRNA is restricted in the adult mouse and humans. In the mouse, expression is seen only in the prostatic lobes and the bulbourethral gland (7). Expression in humans was seen predominantly in the prostate, but low levels of mRNA were also detected in testis (1). There also appeared to be signals in peripheral blood lymphocytes (1). In fact, our attempts to use NKX3.1 as a prostate-specific marker failed because reverse transcription-PCR detected transcripts in female peripheral blood.\(^6\) To clarify the expression of NKX3.1 in human tissues, we did immunohistochemical staining of 16 human tissues, including prostate, brain, heart, lung, kidney, testis, bladder, ureter, skin, liver, spleen, bone marrow, small and large intestine, breast, and endometrium, using our rabbit antiserum. On the basis of preliminary studies with LNCaP cells and NKX3.1-transfected TSU-Prl cells, we expected to find this homeobox protein localized to the nucleus.

We detected expression of NKX3.1 in testis, confirming the results for mRNA expression (Fig. 2, *A* and *B*). We also noted expression of NKX3.1 in rare mucous glands of the lung (Fig. 2, *C* and *D*). Lastly, we found expression of NKX3.1 in groups of urethral epithelial cells periodically spaced along the lumen of the ureter (Fig. 2, *E* and *F*). Bladder transitional epithelium contained rare single cells with nu-

---

5. H. J. Voeller and E. P. Gelmann, unpublished data.

clear staining (not shown). We found no expression in tissues that contained blood cells, including bone marrow and spleen. Nonmalignant prostatic epithelial cells had uniformly positive nuclear staining for NKX3.1. This was seen in 61 RP specimens (Fig. 2, G and H).

To determine the expression of NKX3.1 in neoplastic prostate epithelium, we analyzed a tissue microarray that contained a spectrum of tissue samples providing a cross-section of prostate tumor progression. To validate the data in the array from one category of tissue, we performed conventional immunohistochemical staining on a separate set of 61 embedded tissue blocks from prostatectomy specimens. Thirty of these blocks contained malignant foci that were scored for NKX3.1 expression and compared with the results of the RP samples in the tissue microarray.

Neoplastic prostate epithelium was found to display three different patterns of immunostaining for NKX3.1 expression. Many samples stained uniformly for NKX3.1. Some samples stained heterogeneously, with some malignant cells stained and adjacent cells not stained. Some samples displayed no staining for NKX3.1. In samples in which malignant cells did not express NKX3.1, adjacent normal epithelial cells were invariably positive, providing an internal control for the quality of the specimen. The patterns of staining are shown in Fig. 3. For the purposes of analyzing the 477 microarray samples and the 30 sections, uniform staining was awarded a score of 2, heterogeneous staining a score of 1, and samples that did not stain were scored 0.

The results of staining for the tissue microarray are shown in Table 1. Whereas the majority of samples from early-stage cancers stained uniformly for NKX3.1 in epithelial cell nuclei, the number of samples with heterogeneous or negative staining increased among the locally advanced T3/4 and HR samples. There was a significant reduction of NKX3.1 expression in advanced prostate cancer as defined by either HR \( (P < 0.0001) \) or metastatic disease \( (P < 0.0001) \). HR demonstrated significantly lower NKX3.1 expression than BPH \( (P < 0.0001) \), T1\textsubscript{ab} \( (P < 0.0001) \), and RP \( (P = 0.013) \). Metastatic samples differed from all tissue samples BPH through T3/4 \( (P < 0.0001 \text{ for each}) \). The combined group of T1\textsubscript{ab} tumors and RP samples had significantly higher NKX3.1 expression than metastases \( (P < 0.0001) \) but did not achieve a significant difference compared with T3/4 \( (P = 0.061; \text{Ref. 13, 14}) \).

Seventy-eight percent of metastatic samples had no staining for NKX3.1. The integrity of these autopsy samples was confirmed by staining for Ki-67, which was seen to decorate nearly all of the metastatic samples. Because Ki-67 may be more stable than NKX3.1 under conditions found at autopsy, we also compared the HR speci-
However, staining of HR autopsy specimens scored positive twice as often as staining of autopsy-derived metastases.

The series of 30 RP specimens analyzed as conventional sections cut from paraffin blocks gave nearly identical results to the distribution of staining patterns found among the RP specimens in the tissue microarray. The microarray RP samples gave a nearly identical distribution of staining scores compared to these 30 paraffin block samples; therefore, the staining of conventional samples validated the tissue microarray data and confirmed that a fraction of early-stage prostate cancers lose expression of NKX3.1.

The 30 samples from paraffin blocks were subjected to histological grading (11). In contrast to the relationship between loss of NKX3.1 staining and prostate tumor progression, we found no relationship between NKX3.1 staining scores and Gleason scores in the 30 RP blocks. The distribution of NKX3.1 staining results over the range of tumor grades as measured by Gleason score is shown in Table 2. Samples were compared across all scores and compared as groups with at least one grade ≥4 versus both grades <4. There was no evidence indicating that patients with lower NKX3.1 expression had higher Gleason scores ($P = 0.611$; Ref. 13).

**DISCUSSION**

Our data show that NKX3.1 expression is lost in a significant fraction of early-stage prostate cancer and that loss of expression correlates with tumor progression. Because NKX3.1 has differentiating and growth-suppressing effects in the mouse prostate, it is tempting to speculate that NKX3.1 plays a tumor-suppressor function in human prostate cancer. If, similar to the mouse, the human prostatic epithelium is sensitive to the level of NKX3.1 protein, then diminution in the level of NKX3.1 expression, even in tissues that demonstrate heterogeneous staining, may play a role in the pathogenesis or progression of human prostate cancer. NKX3.1 staining was found in three patterns in the tissue samples. Most samples, except for metastases, showed diffuse staining of both normal and neoplastic prostatic epithelial cells. In our experience, all normal prostate epithelial cells express NKX3.1. NKX3.1 expression decreases with disease severity. That fact combined with the lack of relationship between NKX3.1 expression and the Gleason score means that NKX3.1 expression has the potential to be a promising new prognostic marker if it is associated with patient survival. Further studies are warranted in this area. A previous report that $NKX3.1$ mRNA expression was increased in prostate cancer tissues compared with adjacent normal tissues arrived at a different conclusion from our findings (8). If the results of Xu et al. (8) are confirmed, it would lead to the conclusion that control of NKX3.1 expression occurs at the posttranscriptional level.

In the survey of 61 tissue sections, we found no example of

<table>
<thead>
<tr>
<th>A. Score</th>
<th>H&amp;E</th>
<th>IHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>![H&amp;E image]</td>
<td>![IHC image]</td>
</tr>
<tr>
<td>1</td>
<td>![H&amp;E image]</td>
<td>![IHC image]</td>
</tr>
<tr>
<td>0</td>
<td>![H&amp;E image]</td>
<td>![IHC image]</td>
</tr>
</tbody>
</table>

Fig. 3. Immunohistochemical staining of prostatic tissue and tissue microarrays with anti-NKX3.1. A, examples of prostate cancer specimens from tissue microarrays stained with H&E (left) and corresponding section stained with anti-NKX3.1 (right). Staining patterns observed were diffuse staining (2), heterogeneous staining (1), or no staining (0). All tissues were scored according to this scheme, and the data are summarized in Table 1. B, parallel sections from a Gleason score 3 + 3 prostate cancer specimen stained with H&E (left) and corresponding section stained with anti-NKX3.1.

**Table 1** Frequencies of progression array staining for NKX3.1

<table>
<thead>
<tr>
<th>NKX3.1 staining score</th>
<th>BPH</th>
<th>PIN</th>
<th>T1ab</th>
<th>RP</th>
<th>T3/4</th>
<th>HR</th>
<th>Meta</th>
<th>RP sections</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>36</td>
<td>9</td>
<td>83</td>
<td>68</td>
<td>14</td>
<td>64</td>
<td>4</td>
<td>19</td>
<td>63</td>
</tr>
<tr>
<td>1</td>
<td>5</td>
<td>7</td>
<td>19</td>
<td>24</td>
<td>7</td>
<td>20</td>
<td>5</td>
<td>7</td>
<td>23</td>
</tr>
<tr>
<td>0</td>
<td>2</td>
<td>4</td>
<td>7</td>
<td>18</td>
<td>6</td>
<td>44</td>
<td>31</td>
<td>4</td>
<td>13</td>
</tr>
<tr>
<td>Total (100%) tissue</td>
<td>43</td>
<td>20</td>
<td>109</td>
<td>110</td>
<td>27</td>
<td>128</td>
<td>40</td>
<td>30</td>
<td></td>
</tr>
</tbody>
</table>

| HR                    | <0.0001<sup>a</sup> | 0.789 | <0.0001<sup>a</sup> | 0.013<sup>b</sup> | 0.529 |
| Meta                 | <0.0001<sup>a</sup> | <0.0001<sup>a</sup> | <0.0001<sup>a</sup> | <0.0001<sup>a</sup> | 0.061 |
| T1ab + RP            | <0.0001<sup>a</sup> |       |       |       |      |

<sup>a</sup> RP samples from tissue microarray and paraffin sections presented similar NKX3.1 score profiles.

<sup>b</sup> Meta, metastatic disease.

<sup>c</sup> This test is significant at 0.05. No adjustment was made because these analyses were controlled by the overall test.

<sup>d</sup> This test is significant at the specified $P < 0.025$. 6114
expression occurs in many regions of the Nkx3.1 murine development, expression of the SV40 T antigen (17-19). Whether the Nkx3.1 promoter may have applications potentially useful determinant for prostate-specific expression of ex-pression of NKX3.1 in organs other than the prostate will have any use of suppressor genes with limited tissue-specific effects to mini-cancer is under active investigation. There may be advantages to the use of NKX3.1 in prostate cancer development. The finding that Nkx3.1 expression was lost most often in metastases is consistent with the notion that metastatic disease is the most dedifferentiated state of prostate cancer. It may also be that Nkx3.1 expression is under the control of prostate stromal cells. In murine tissue recombinants of neonatal epithelium and mesenchyme from the urogenital sinus, only tissues that underwent prostatic differentiation expressed Nkx3.1 (7). On the other hand, the quality of the specimens, particularly from autopsies, could have resulted in sample degradation and diminished ability to detect Nkx3.1. The mechanism of modu-lating Nkx3.1 expression in human prostate cancer remains to be elucidated. It has not been determined whether Nkx3.1 undergoes LOH in those tissues that display LOH at 8p21. Therefore, it is possible that loss of a single Nkx3.1 allele as a result of LOH at 8p21 could down-regulate Nkx3.1 expression. Because Nkx3.1 is a differentiating protein, its expression may be regulated by gene methylation. We presently are characterizing the upstream sequences of Nkx3.1 to identify regions that may be targets for gene silencing by methylation. Methylation is an important mechanism for loss of differentiated functions in human cancers such as diminished estrogen-receptor expression in breast cancer (15, 16). It remains to be determined whether promoter methylation plays a role in the down-regulation of Nkx3.1 expression in prostate cancer.

The survey of Nkx3.1 expression in normal tissues underscores the high degree of prostate specificity in the expression pattern of this protein. The role of Nkx3.1 in the function of extraprostatic cells where it was found, bronchial mucous glands, testis, and ureter, is unknown. Nkx3.1 is not expressed in murine testis, and the Nkx3.1 (−/−) mice were fertile. There was no obvious ureteral or pulmonary pathology attributed to loss of Nkx3.1 in the gene-deleted mice (7). If the only apparent action of Nkx3.1 is as a prostate-specific repressor, the gene may have application in prostate-specific gene therapy. The potential for application of gene therapy to the treatment of prostate cancer is under active investigation. There may be advantages to the use of suppressor genes with limited tissue-specific effects to mini-mize toxicity of gene therapy to other organs. Whether ectopic expression of Nkx3.1 in organs other than the prostate will have any functional ramifications remains to be shown. In addition, because of its tissue-specific expression in the adult, the Nkx3.1 promoter is a potentially useful determinant for prostate-specific expression of exogenous genes. The probasin promoter has been quite useful in generating a murine prostate cancer model by driving organ-specific expression of the SV40 T antigen (17-19). Whether the Nkx3.1 promoter will have similar effects remains to be shown. Early in murine development, Nkx3.1 expression occurs in many regions of the embryo and may play a noncritical role in the development of other organs (20, 21). Lastly, the Nkx3.1 promoter may have applications in tissue-specific gene therapy of prostatic disease. The expression of Nkx3.1 in other tissues shown in this report will help to identify potential organs for side effects of treatments targeted to the prostate by the Nkx3.1 promoter.

ACKNOWLEDGMENTS

The Lombardi Cancer Center Histopathology and Tissue Shared Resource provided normal human tissues. We are particularly grateful to Baljit Singh for assistance. Microscopy was done in the Lombardi Cancer Center Microscopy and Imaging Shared Resource.

REFERENCES


